- Home
- CRT vs RNXT Comparison
CRT vs RNXT Comparison
Compare CRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- RNXT
- Stock Information
- Founded
- CRT 1991
- RNXT 2012
- Country
- CRT United States
- RNXT United States
- Employees
- CRT N/A
- RNXT N/A
- Industry
- CRT Oil & Gas Production
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- RNXT Health Care
- Exchange
- CRT Nasdaq
- RNXT Nasdaq
- Market Cap
- CRT 45.2M
- RNXT 40.7M
- IPO Year
- CRT 1992
- RNXT 2021
- Fundamental
- Price
- CRT $7.11
- RNXT $1.20
- Analyst Decision
- CRT
- RNXT Strong Buy
- Analyst Count
- CRT 0
- RNXT 2
- Target Price
- CRT N/A
- RNXT $7.50
- AVG Volume (30 Days)
- CRT 27.3K
- RNXT 679.7K
- Earning Date
- CRT 01-01-0001
- RNXT 11-12-2025
- Dividend Yield
- CRT 10.37%
- RNXT N/A
- EPS Growth
- CRT N/A
- RNXT N/A
- EPS
- CRT 0.92
- RNXT N/A
- Revenue
- CRT $6,559,820.00
- RNXT $662,000.00
- Revenue This Year
- CRT N/A
- RNXT $2,895.35
- Revenue Next Year
- CRT N/A
- RNXT $313.04
- P/E Ratio
- CRT $7.78
- RNXT N/A
- Revenue Growth
- CRT N/A
- RNXT N/A
- 52 Week Low
- CRT $7.12
- RNXT $0.75
- 52 Week High
- CRT $13.31
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- CRT 27.77
- RNXT 49.29
- Support Level
- CRT $7.38
- RNXT $1.11
- Resistance Level
- CRT $7.72
- RNXT $1.15
- Average True Range (ATR)
- CRT 0.18
- RNXT 0.11
- MACD
- CRT -0.00
- RNXT -0.01
- Stochastic Oscillator
- CRT 5.88
- RNXT 35.62
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.